Other Clinical Trial - Exercise Capacity Improvement by Conduction System

Status Recruiting

Clinical Trial Summary

This randomized controlled trial aims to investigate the impact of conduction system pacing in comparison to right ventricular apical pacing on exercise capacity, as measured by peak oxygen uptake (VO2peak), in heart failure patients with indication for pacing but no compelling indication for cardiac resynchronization therapy (CRT). The mechanisms of exercise intolerance in heart failure patients influenced by conduction system pacing will be assessed.

Clinical Trial Description

Heart failure (HF) is a serious condition that affects a lot of people and places a significant burden on the healthcare system. Some HF patients also have issues with the natural electrical system of their heart, causing uneven heart contractions and worsening heart function. A treatment known as CRT has been helping such patients, but it does not work for everyone. A new technique called conduction system pacing (CSP) has emerged that might offer a more natural way of maintaining heart contractions. This study aims to determine if CSP can enhance the ability of HF patients to exercise, by looking at their maximum oxygen consumption (a measure of exercise capacity). It will also explore why some HF patients struggle with exercise more than others. Eligible patients will be randomly assigned to either the new CSP treatment or a standard pacing method (right ventricular apical pacing). Patients will be checked regularly over a follow-up period of 24 weeks. The main goal is to see if patients can exercise better with CSP after 24 weeks. The study will also look at other heart measures and safety concerns related to the devices. This study might show that CSP can help improve exercise capacity and heart function in certain HF patients. The results could guide health care professionals in offering better, tailored treatments for their patients. ;

Study Design

Related Conditions & MeSH terms

Heart Failure
Heart Failure With Preserved Ejection Fraction
Heart Failure With Reduced Ejection Fraction

Clinical Trial Details

NCT number	NCT06278844
Study type	Interventional
Source	University Hospital, Antwerp
Contact	Andreas Gevaert
Phone	038213538
Email	Andreas.gevaert@uza.be
Status	Recruiting
Phase	N/A
Start date	December 12, 2023
Completion date	December 2027

View Details

See also
Status	Clinical Trial	Phase
Suspended	`NCT05839730` - Fast Induced Remodeling in Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT05095688` - Relationship Between Adipose Tissue Distribution and Arterial Stiffness in HFpEF
Recruiting	`NCT06379152` - Effect of Bilirubin on Prognosis in Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05676684` - Dapagliflozin, Spironolactone or Both for HFpEF	Phase 2/Phase 3
Recruiting	`NCT04153136` - Effects of Sacubitril/Valsartan on Subclinical Heart Failure in HIV (The ENCHANTMENT HIV Study)	Phase 2
Recruiting	`NCT06114498` - Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
Recruiting	`NCT05715697` - Renal Denervation in Patients With Chronic Heart Failure With Preserved Ejection Fraction	N/A
Recruiting	`NCT04745013` - PeRsonalIzed remOtely Guided Preventive exeRcIse Therapy for a healThY Heart	N/A
Completed	`NCT05126836` - Cilostazol for HFpEF	Phase 2
Completed	`NCT05586828` - A Single-center Retrospective Cohort Study to Explore the Prognostic Significance of CONUT in Elderly CAD Patients With HFpEFand Compare CONUT With Other Objective Nutritional Indices.
Recruiting	`NCT04594499` - The Relationship Between Pericardial Fat Thickness and Arterial Stiffness in HFpEF Patients
Active, not recruiting	`NCT05204238` - Follow Up of acuTe Heart failUre: a pRospective Echocardiographic and Clinical Study (FUTURE)
Completed	`NCT04535726` - The Relationship Between Blood Pressure and Arterial Stiffness in HFpEF Patients With Different Levels of Obesity
Recruiting	`NCT03550235` - Exploration of Dyspnea at Non-high Brain Natriuretic Peptide (BNP)
Completed	`NCT04633460` - Acute Effects of Exogenous Ketone Ester Administration in Heart Failure	Phase 2
Completed	`NCT06228807` - Clinical Characteristics and Predictors of Adverse Outcomes in HFpEF
Active, not recruiting	`NCT05284617` - Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF	Phase 2
Recruiting	`NCT05562063` - Sotagliflozin in Heart Failure With Preserved Ejection Fraction (HFpEF) Patients	Phase 4
Recruiting	`NCT06027307` - Enavogliflozin Outcome Trial in Functional Tricuspid Regurgitation	Phase 3
Recruiting	`NCT05582044` - Exercise Lower-body Negative Pressure in Heart Failure With Preserved Ejection Fraction	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Exercise Capacity Improvement by Conduction System Pacing in heArt Failure patieNts Without Compelling CRT inDication — ESCPAND

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms